Resources
Life Saving Drugs Program – HT1 – Review summary and Expert Panel recommendations
This HT1 review considered nitisinone (only the brand Orfadin® was in scope for the review). The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.
Life Saving Drugs Program – HT1 – Review summary and Expert Panel recommendations for consumers
This HT1 review considered nitisinone (only the brand Orfadin® was in scope for the review). The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Life Saving Drugs Program – Gaucher disease – Review summary and expert panel recommendations for consumers
This Gaucher disease review considered 3 enzyme replacement therapies (ERTs), imiglucerase, velaglucerase and taliglucerase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health.
Life Saving Drugs Program – MPS II – Review summary and expert panel recommendations
This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.
Life Saving Drugs Program – MPS II – Review summary and expert panel recommendations for consumers
This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Life Saving Drugs Program – Pompe disease – Review summary and expert panel recommendations
This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.
Life Saving Drugs Program – Pompe disease – Review summary and expert panel recommendations for consumers
This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Life Saving Drugs Program – Gaucher disease – Review summary and expert panel recommendations
This Gaucher disease review considered three enzyme replacement therapies (ERTs), imiglucerase, velaglucerase and taliglucerase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.
Life Saving Drugs Program – Fact sheet for pharmacists
This fact sheet gives answers to common questions about the role of pharmacies and authorised persons in managing Life Saving Drugs Program (LSDP) medicines.
Life Saving Drugs Program – MPS I – Review summary and expert panel recommendations for consumers
This MPS I review considered laronidase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Life Saving Drugs Program – MPS I – Review summary and expert panel recommendations
This MPS I review considered laronidase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.
Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations for consumers
This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumer
Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations
This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. These documents provide a summary of the review findings and recommendations.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 17 February 2023
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 14th meeting on 17 February 2023.
healthdirect symptom checker
Use this tool if you’re feeling unwell and not sure what to do – if it’s an emergency, call 000 immediately. Answer some questions about your symptoms and get advice on whether to see a doctor, go to hospital or call an ambulance. It is available online at any time.
The Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK)
You can use the AUSDRISK tool to estimate your risk of getting type 2 diabetes in the next 5 years.
6:30
Top 3 questions – Healthy lifestyle choices
Professor Michael Kidd, Deputy Chief Medical Officer, discusses making healthy choices, and the small steps we can take every day to enjoy a healthy life.
5:44
Top 3 questions – Chronic Conditions
Hear Doctor Lucas De Toca, COVID-19 Primary Care Response First Assistant Secretary, talk about chronic illness.
00:06:33
Top 3 questions – Men's Health Week with Dr Lucas de Toca (Part 1)
Hear from Dr Lucas de Toca talk about whether men are more susceptible to certain illnesses or conditions compared to women, and when men should start regular health checks and screening tests.
00:07:12
Top 3 questions – Men's Health Week with Dr Lucas de Toca (Part 2)
In celebration of Men’s Health Week, hear from Dr Lucas de Toca on how family history and lifestyle impact our health and learn tips to help maintain a healthy lifestyle.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 14 October 2022
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 13th meeting on 14 October 2022
Life Saving Drugs Program – Avalglucosidase alfa (Nexviazyme®) outcome statement
Summary of the consideration of the application from Sanofi Pty Ltd for the inclusion of avalglucosidase alfa (Nexviazyme®) on the Life Saving Drugs Program (LSDP) for the treatment of Pompe Disease.
Elosulfase alfa Terms of Reference and Protocol Questions
This report outlines the Elosulfase alfa 24 Month Review Terms of Reference and Protocol Questions
Providing health care to a thalidomide survivor fact sheet
This fact sheet is designed to help facilitate discussions between thalidomide survivors and their health care practitioners.
Coronavirus (COVID-19) at a glance – 20 June 2022
This infographic provides a quick view of the coronavirus (COVID-19) situation in Australia on 20 June 2022
Date last updated: